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I. Introduction 
 We have reached a new frontier in the field of genetics. A groundbreaking piece 
of biotechnology has recently been discovered that can change the genetic code of an 
organism in the blink of an eye. The name of the technology is CRISPR-Cas9, and it  
is attracting attention from scientists and researchers around the world as the newest and 
most efficient piece of genome editing technology available. CRISPR-Cas9 can create 
double- stranded breaks in DNA at precise locations within an organism’s genome, 
allowing genes to be added and deleted from that spot with better accuracy and more 
precision than ever before.  
 CRISPR-Cas9 has opened up the door for innovation in the fields of clean energy,  
drug development, agriculture, and human medicine. In medicine, scientists have  
contemplated using CRISPR-Cas9 clinically on human embryos to delete deleterious  
genes and add in healthy ones in the hopes of preventing genetic disease. This type of  
therapy on embryos is called germline gene editing because it involves creating changes  
in the germline cells of embryos that will be inherited by future generations. While  
somatic cell therapies alter non-reproductive cells and thus affect only the one patient,  
germline therapy in contrast can affect the DNA of the patient’s children, grandchildren  
and even great grandchildren.  
 Creating a change in germline DNA is humans no inconsequential matter. Many 
things about a person will be determined or at the very least greatly affected by their 
DNA.  For instance their phenotype (how they physically appear) as well as their 
physical health are both directly related to the DNA that they inherit from their biological 
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mother and father. The stakes are high and many concerns involving the safety and ethics 
of using CRISPR-Cas9 to edit the human germline exist, rightfully. 
 Due to these safety concerns, no research team has been comfortable using 
CRISPR-Cas9 technology to tamper with human life in this way. For many, it 
represented a clear red line not to be crossed. However, on April 18th, 2015 one Chinese 
research team took a leap of faith.     
  A group of scientists from Sun Yat-sen University in Guangzhou, China shocked 
the scientific community by publishing a paper detailing research they carried out using 
CRISPR-Cas9 to edit the genomes of human zygotes. They had attempted to correct for a 
mutation responsible for the fatal blood disorder Beta thalassemia by removing the 
disease-causing gene from the zygote’s DNA.  
  The results of the experiment were very mixed. A high number of “off-target” 
mutations (unanticipated changes in the DNA) occurred. This was concerning, given that 
the occurrence of enough off target effects can interfere with the proper functioning of 
other healthy genes. Furthermore, the CRISPR-Cas9 therapy was not able to correct for 
the mutation in all cells, so in some embryos only about half of the cells were edited 
successfully.  
 Protests and cries for this research to stop ensued as scientists and other interested 
parties struggled to wrap their heads around what had just taken place and its’ 
implications. Many worried this experiment signaled research was progressing too 
quickly, and they feared CRISPR-Cas9 would be used prematurely on embryos and cause 
serious genetic defects. After the study was published, the National Institutes of Health in 
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the United States reiterated their position on the matter by reaffirming that they would not 
fund any gene-editing research using human embryos.1  
 While the experiment coming out of China used CRISPR-Cas9 for research 
purposes only, with no intention of implanting the embryo into a woman, the prospect of 
CRISPR edited babies being born is not too far off. There are realistic situations where 
CRIPSR-Cas9 could serve as a valuable piece of preventative medicine, thus it is fair to 
assume that there may be a growing demand for this technology in the near future. For 
instance, in rare cases where both parents are carriers for genetic disease and none of 
their embryos are disease free, CRISPR-Cas9 therapy may be the only option for the 
couple to have a healthy and genetically related child.  
 Though CRISPR technology holds great potential, the last thing anyone would 
want would be to inadvertently harm future children with its’ use. To avoid possible fetal 
harm, some scientists want to call off all research using the CRISPR system on human 
zygotes and ban clinical application of CRISPR-Cas9 forever. Marcy Darnovsky, 
executive director of the non-profit Centre for Genetics and Society in Berkeley, 
California wrote, “No researcher has the moral warrant to flout the globally widespread 
policy agreement against altering the human germline.” Hille Haker, Chair of Moral 
Theology from Loyola University agreed with this statement, arguing that reproductive 
germline editing should be banned because it is unethical and exposes women and 
children to non-justifiable health risks.2  
																																																								1	Cressey, D., Abbott, A., & Ledford, H. (2015). UK scientists apply for license to edit genes in human 
embryos. Nature. Retrieved from http://www.nature.com/news/uk-scientists-apply-for-licence-to-edit-
genes-in-human-embryos-1.18394	2	Haker,	Hille	(2015,	December	1) Societal Implications of Emerging Technologies	[Video file]. Retrieved	from	https://vimeo.com/album/3703972/video/149190913	
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 On March 12, 2015, upon hearing rumors about the experiment on human zygotes 
coming out of China, a prominent group of scientists from the United States also argued 
for a halt on research and clinical application of CRISPR-Cas93.  The members of the 
group consisted of Edward Lanphier (one of the scientists responsible for developing a 
technological predecessor to CRISPR-Cas9) and four of his colleagues. They expressed 
concern over the safety and ethics of CRISPR, and argued that the possible risks 
associated with the technology outweighed all of the potential benefits. They felt that the 
unpredictable effects that CRISPR could have on future generations made it “dangerous 
and ethically unacceptable”4 to use on human embryos.  This particular group of 
scientists also pushed for a moratorium on research involving human zygotes because 
they feared that if something went wrong so early on in research, a backlash against 
germline genetic modification with CRISPR- Cas9 technology could hinder all future 
research.  
  On March 19th, 2015, a different group comprised of 18 prominent American 
scientists published a document supporting previous calls for a ban on clinical application 
of CRISPR-Cas9 technology on the human germline.5 They took a more permissive 
stance in terms of research however, giving the message: proceed with caution.  
 While many scientists are trying to put the breaks on CRISPR-Cas9, there are 
others in who want it to be available for use on human zygotes as soon as possible. Those 
in this camp include more liberal scientists, patients suffering from genetic diseases 
themselves, and family members of those who are afflicted. For example, Sarah Gray, 																																																								3	Lanphier,	E.	et	al.	(2015)	Don’t	edit	the	human	germ	line.	Nature	519	(7544).		4	Ibid.			5	Baltimore,	D.	et	al.	(2015)	A	prudent	path	forward	for	genomic	engineering	and	germline	gene	modification.	Science	348,	36-38		
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who lost her son who was six days old to a deadly genetic disease, tearfully implored, “ if 
you have the skills and knowledge to fix these diseases, then do it!”  Additionally, 
bioethicist John Harris said in favor of continuing with CRISPR research, “I don’t see 
any justification for a moratorium on research, it’s no worse than what happens in IVF all 
the time.” 6 
 All of the discussions circulating in the spring of 2015 over CRIPSR-Cas9 were 
synthesized during winter of the same year during an International Summit on Human 
Gene Editing that took place from December 1st to the 3rd. This summit, a first of its 
kind, was held in Washington D.C. and was cohosted by the Chinese Academy of 
Sciences, the Royal Society of the UK, and the US National Academy of Sciences and 
Medicine. An outstanding turnout of nearly 500 scientists, ethicists, legal experts, and 
advocacy groups from almost 20 different countries discussed safety, ethical, and 
regulatory issues surrounding human germline gene editing research and clinical 
application tirelessly for three days.  
 The summit represented a groundbreaking step in shaping the future interface 
between CRIPSR-Cas9 technology and the human genome. The main question that the 
members of the summit wrestled with was how to proceed forward with regulation of 
CRISPR-Cas9 technology in a way that would ensure patient safety and uphold ethical 
standards. There were a variety of opinions presented ranging from a complete ban on the 
technology to little or no regulation at all.  
 At the end, a statement was released by the heads of the organizing committee 
which stated that while research could continue on germline gene editing, it would be 																																																								6	Cyranoski, D., & Reardon, S. (2015). Embryo Editing Sparks Epic Debate. Nature. Retrieved April 20, 
2016, from http://www.nature.com/news/embryo-editing-sparks-epic-debate-1.17421  	
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irresponsible at this time to proceed with the clinical application of the technology until 
all safety issues were cleared up and there was broad societal consensus that this was an 
appropriate technology to use. 7  
 I stand behind this statement issued by the heads of the International Summit on 
Human Gene Editing. In my thesis I will argue for the continuation of carefully 
monitored research using human zygotes along with the imposition of a temporary ban on 
the clinical application of CRIPSR-Cas9 until it reaches an agreed upon safety standard. 
Safe research, approved first by an advisory board is the best way to protect human 
embryos and allow CRISPR-Cas9 technology to reach its full potential as a valuable 
piece of preventative medicine.  
 While the genetic modification of embryos using CRISPR-Cas9 is not a safe 
enough process to be carried out clinically right now, the permanent banning of CRISPR-
Cas9 facilitated germline genetic modification is not the route to go either. Doing so 
would only stifle a technology that could have real benefit for couples affected with 
genetic disease that could not have a healthy genetically related child any other way. I 
thus aim to contextualize and qualify certain safety and ethical claims made against 
CRISPR-Cas9 to balance out the predominantly negative discourse surrounding its’ use.   
 In my first chapter I detail the multistep development of the CRISPR-Cas9 system 
and highlight notable research that has been successfully carried out with its’ help.  I 
provide an explanation of how the system itself works from a biological level, and 
include how it could be used in a medical setting to prevent heritable disease.  
																																																								7	On Human Gene Editing: International Summit Statement. (2015, December 3). Retrieved from 
http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=12032015a  	
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 Next, I review relevant safety concerns involving the use of CRISPR-Cas9 gene 
editing technology on human zygotes, looking at the April 2015 experiment with 
triponuclear zygotes that came out of China as well as other research that has been done. 
This section will emphasize existing safety concerns that exist with the technology, but 
will also offer a look at ways in which the technology could be improved so that off 
target mutations would be less likely to occur.   
 After this, I delve into the bioethics of using CRISPR technology to edit the 
human germline. I compare the ethical debates surrounding CRISPR-Cas9 to other 
debates brought up by previous reproductive technologies such as IVF. By illuminating 
threads of similarity and digging into claims made against CRISPR, I aim to qualify 
ethical concerns triggered by the prospect of using CRISPR-Cas9 to edit human embryos.  
 Finally, in my conclusion I summarize the major points of my thesis and discuss 
the prospect of moving forward with the clinical application of CRISPR-Cas9 on human 
zygotes what should take place first in terms of regulation before that occurs.  
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II. Contextualizing CRISPR 
Development 
 The discovery of the CRISPR-Cas adaptive immunity system and its subsequent 
development into a genome-editing tool represents the cumulative work of scientists 
across the globe.8  
 The story begins in 1993 off of Spain’s Costa Blanca where researcher Francisco 
Mojica was the first to characterize a CRISPR locus. Later, in 2005 he reported that 
CRISPR sequences match snippets from the genomes of bacteriophages9, leading him 
hypothesize (correctly) that CRISPR is an adaptive immune system for bacteria.10 This 
same year Alexander Bolotin from the French National Institute for Agricultural 
Research was studying the sequence array of an unusual CRISPR locus in the bacteria 
Streptococcus thermophilus.  He noticed that this unique locus contained a novel Cas 
gene that coded for a protein with nuclease activity (now known as Cas9).11 
 By 2007 Philippe Horvath and his colleagues had proved Francisco Mojica’s 
hypothesis correct that CRISPRs are indeed adaptive immune systems for bacteria12, and 
																																																								8	CRISPR Timeline. (2016). Retrieved from https://www.broadinstitute.org/what-broad/areas-
focus/project-spotlight/crispr-timeline  9	Mojica, F.J.M., D ez-Villase or, C.S., Garc a-Mart nez, J.S., and Soria, E. (2005). Intervening Sequences 
of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements. J Mol Evol 60, 174–182. 10	CRISPR Timeline. (2016). Retrieved from https://www.broadinstitute.org/what-broad/areas-
focus/project-spotlight/crispr-timeline	11	Ibid	12	CRISPR Timeline. (2016). Retrieved from https://www.broadinstitute.org/what-broad/areas-
focus/project-spotlight/crispr-timeline	
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they work by incorporating the attacking phage’s DNA into their CRISPR array,13 
allowing them to have a memory system in place so they can effectively destroy the next 
phage when it invades the bacteria.    
 In 2008 researcher John van der Oost and his team found that Cas proteins are 
guided to target DNA by CRISPR RNAs (crRNA). 14 Two years later, Sylvain Moineau 
from the University of Laval in Quebec City, demonstrated that CRISPR-Cas9 could 
create double stranded breaks in target DNA at precise locations. Moineau’s team also 
confirmed that Cas9 is the only protein required for cleavage. 15  
 In 2011 Emmanuelle Charpentier and her colleagues showed that in addition to 
the crRNA, another RNA is necessary to cut the target DNA. They called this the trans-
activating CRISPR RNA (tracrRNA)16. The tracrRNA forms a duplex with crRNA, and 
this duplex guides the Cas9 to its targets.17 Emmanuelle Charpentier teamed up with 
Jennifer Doudna and in 2012 they came up with the idea of combining crRNA and 
trRNA to create a single, simple system. Then in 2013, Feng Zhang and his colleagues 
from the Broad Institute of MIT and Harvard became the first team to successfully adapt 
the CRISPR-Cas9 system for genome editing purposes in eukaryotic cells18 They also 																																																								13	Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D.A., and 
Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 
1709–1712. 14	Brouns, S.J., Jore, M.M., Lundgren, M., Westra, E.R., Slijkhuis, R.J., Snijders, A.P., Dickman, M.J., 
Makarova, K.S., Koonin, E.V., van der Oost, J. (2008) Small CRISPR RNAs guide antiviral defense in 
prokaryotes. Science 321, 960-964. 15	CRISPR Timeline. (2016). Retrieved from https://www.broadinstitute.org/what-broad/areas-
focus/project-spotlight/crispr-timeline	16	Deltcheva, E., Chylinski, K., Sharma, C.M., Gonzales, K., Chao, Y., Pirzada, Z.A., Eckert, M.R., Vogel, 
J., and Charpentier, E. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor 
RNase III. Nature 471, 602–607. 17	Ibid	18	Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, 
L.A., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823. 
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showed that the system could be programmed to target multiple locations in the genome 
and that it could drive homology-directed repair.19 
  It was around this time that CRISPR research began take off. Scientists began to 
use CRISPR-Cas9 to genetically engineer model organisms in the lab including mice, 
zebra fish, fruit flies, yeast, plants, pigs, and Rhesus monkeys.20  
 To date, various experiments that demonstrate the promise of CRISPR-Cas9 have 
been carried out successfully. In one instance, a mutation in the Crygc gene that is 
responsible for cataracts was successfully corrected by deletion of the mutated allele and 
insertion of healthy base pairs in mice.21 In another experiment, Robinson (2016) found 
that CRISPR-Cas9 could correct the dystrophin mutation in a mouse model of Duchenne 
muscular dystrophy.22   
 In addition, the mutation responsible for cystic fibrosis was also corrected in adult 
intestinal stem cells taken from cystic fibrosis patients by deletion,23 showing the promise 
of this technology in eradicating devastating heritable diseases such as cystic fibrosis in 
human embryos.  
 
 How does the CRIPSR-Cas9 system Work?  																																																																																																																																																																						19	CRISPR Timeline. (2016). Retrieved from https://www.broadinstitute.org/what-broad/areas-
focus/project-spotlight/crispr-timeline	20	Year in review: Breakthrough gene editor sparks ethics debate. (2015, December 15). Retrieved March 
30, 2016, from https://www.sciencenews.org/article/year-review-breakthrough-gene-editor-sparks-ethics-
debate  21	Y.	Wu	et	al.,	Correction	of	a	genetic	disease	in	mouse	via	use	of	CRISPR-Cas9.	Cell	Stem	Cell	13,	659–662	(2013).	doi:	10.1016/j.stem.2013.10.016;	pmid:	24315440	22	Robinson, R. (2016). Gene Editing with CRISPR/Cas9 Corrects Mutation in Duchenne Muscular 
Dystrophy Model. Neurology Today, 16(3).  23	G.	Schwank	et	al.,	Functional	repair	of	CFTR	by	CRISPR/Cas9	in	intestinal	stem	cell	organoids	of	cystic	fibrosis	patients.	Cell	Stem	Cell	13,	653–658	(2013).	doi:	10.1016/j.stem.2013.11.002;	pmid:	24315439	
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 The CRISPR-Cas9 system works by creating breaks in DNA with the help of the 
“molecular scissor” nuclease Cas-9. The breaks made by Cas-9 are then fixed by the 
cell’s own repair mechanisms. One repair mechanism includes non-homologous end 
joining, which refers to the rejoining of the ends of the broken DNA. It is called “non-
homologous” because the severed ends are directly rejoined without the need for a 
homologous template.  To introduce a new gene, a piece of DNA can be integrated at the 
sight of the cut during this time of repair.24 
 The CRISPR-Cas9 system is based on a natural method used by bacteria to 
protect themselves from invading viruses (called type II CRISPR-Cas system). In this 
system, when a virus invades a bacterium, the bacterium detects the presence of viral 
DNA and immediately produces two short strands of ribonucleic acid (RNA) in response. 
One of these strands is unique because its matches up perfectly with the DNA of the 
invading virus. This is known as the guide RNA, or the crRNA. 25 Next, the two strands 
of RNAs form a complex with the nuclease Cas9. Eventually this complex finds the viral 
DNA sequence that matches the guide RNA sequence and the Cas9 nuclease does its job 
and cuts the target DNA, disabling the virus.26  
 
																																																								24	Reis, A. (2014). CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology. 
Retrieved from https://www.neb.com/tools-and-resources/feature-articles/crispr-cas9-and-targeted-genome-
editing-a-new-era-in-molecular-biology 25	Y. Ishino, et al. (1987) J. Bacteriol. 169, 5429-5433 26	Ibid.  
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 27 
 
 Apart from CRISPR, there are two other main types of nucleases that can create 
double stranded breaks at specific loci in DNA. These include zinc-finger nucleases 
(ZFNs) and transcription activator-like effector nucleases (TALENs). The first 
endonuclease technology to be created for targeted genome modification were ZFNs.28 
Next, TALENs came onto the scene. These nucleases were easier than ZFNs to produce, 
but the protein design required for usage still remained too difficult for widespread use, 
and the financial burden was a barrier as well. CRISPR-Cas9 is unique in terms of its low 
cost. Compared to zinc fingers, which cost $5,000 or more, CRISPR costs as little as $30. 
This is a huge contributing factor to its widespread use in laboratories around the globe. 
 																																																								27	Zhang, F. (Director). (2014). Genome Editing with CRISPR-Cas9 [Motion picture]. USA. 
https://www.youtube.com/watch?v=2pp17E4E-O8 28	Kim,	Y.	G.,	Cha,	J.	&	Chandrasegaran,	S.	1996.	Hybrid	restriction	enzymes:	zinc	finger	fusions	to	Fok	I	cleavage	domain.	Proc.	Natl	Acad.	Sci.	USA	93,	1156–1160. 
Cas9	Nuclease		
Guide	RNA	
Target	DNA	
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29 
 
 The CRISPR-Cas9 system can be manipulated to find and cut almost any target 
gene in mammalian cells. This is done with the simple change of the guide RNA, because 
the guide RNA sequence determines where the system will base pair with the target DNA 
and cut it.  
 One way the CRISPR system could be incredibly useful is in allowing us to 
further understand the function of genes. When the Cas9 cuts the DNA, it tries to repair 
itself. However the repair mechanisms are often error prone, leading to random mutations 
that often disable the gene. This allows researchers to understand its function because by 
knocking out a gene and observing the effects on a cell, researchers can make 
conclusions about the function of that specific gene in the cell.  
 Another use of CRISPR-Cas9 germline therapy could be to avoid or treat genetic 
disease in humans. This is the most controversial use of CRISPR and one that is banned 
in over 40 countries. In the future, if it becomes legal, CRISPR-Cas9 could target, 
																																																								29	Year in review: Breakthrough gene editor sparks ethics debate. (2015, December 15). Retrieved March 
30, 2016, from https://www.sciencenews.org/article/year-review-breakthrough-gene-editor-sparks-ethics-
debate  	
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modify, and edit genomic loci of human zygotes to potentially correct genetic mutations 
that lead to genetic disorders.30 CRISPR-Cas9 holds promise in correcting various genetic 
diseases including the two very well known and devastating genetic conditions 
Huntington’s Disease and Cystic Fibrosis.  
 Huntington’s Disease is a progressive brain disorder caused by a single mutation 
in the HTT gene. Symptoms include uncontrollable movement, problems with cognition, 
and difficulty regulating emotions.31  It is an autosomal dominant disorder, meaning that 
one copy of the defective allele is enough to cause the disease. CRISPR-Cas9 could be 
used to delete the extra bases (CAG) present in the affected gene to restore proper 
functioning of the gene’s protein product. If successful, this could prevent the 
development of Huntington’s Disease in future children. 
 Cystic Fibrosis is also caused by a defect in a single gene (the CFTR gene). This 
gene is responsible for making a protein channel that controls the movement of salt and 
water in and out of the cells of the body. When it is does not function as it should there is 
a build up of thick, sticky mucus which can damage the body’s organs, most commonly 
in the respiratory and digestive system. If CRISPR-Cas9 was used to correct for 
mutations in the CFTR gene there is a chance that the embryo could regain the ability 
produce the proper protein channel and not develop Cystic Fibrosis.   
 If legalized, CRISPR treatment could eventually be carried out in in-vitro 
fertilization clinics. Once an egg is fertilized and a zygote is created in the clinic, 
CRISPR-Cas9 could be used on the zygote to correct for disease. After the procedure is 																																																								30	Doudna, Jennifer, and Emmanuelle Charpentier. "The New Frontier of Genome Engineering with 
CRISPR-Cas9." Science 346.6213 (2014). Web. <www.sciencemag.org>.	31	Huntington Disease. (2016, April 20). Retrieved from https://ghr.nlm.nih.gov/condition/huntington-
disease  
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complete the zygote will likely undergo pre-implantation genetic diagnosis, or PGD, to 
test and make sure that the therapy was successful. After this, the zygote could be 
implanted into a uterus and brought to gestation.   
 There are no international bans in place currently on germline genetic 
modification of human embryos, or even internationally agreed upon guidelines that 
researchers are working by. That being said, most countries have their own regulation 
and bans in place. To get a sense of the situation, below is an image of the international 
regulatory landscape regarding human germline gene modification from Nature. The 
responses reveal a wide range of approaches. In some countries, experimenting with 
human embryos at all would be a criminal offence, whereas in others, almost anything 
would be permissible.32 
 
 
																																																								32	Ledford,H. (2015).Where in the world could the first CRISPR baby be born?. Nature, 530 Retrieved 
February 4, 2016, from http://www.nature.com/news/where-in-the-world-could-the-first-crispr-baby-be-
born-1.18542 	
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 The three major countries most invested in the technology and involved in the 
CRIPSR-Cas9 debate currently are the United States, China, and the UK. No nation has 
attempted to use CRIPSR-Cas9 to edit a human embryo except in a research setting, and 
China is the only nation so far that has done this. Research into germline genetic 
modification is legal in China, however germline modification for the purpose of 
reproduction is prohibited.33 The president of the Chinese Academy of Sciences (CAS) 
reportedly said, 
 
 Both the Chinese scientists and government are aware of the pros and cons 
of human gene editing. CAS scientists have organized panel discussion 
meetings and coordinated with related government agencies for regulatory 
policies on this issue. We would like to work together with international 
communities for the proper regulation and application of such technology. 
(Chunli Bai)  
 
   Additionally, the Chinese Academy of Science has organized several meetings to 
discuss the human genomic editing and the proper use of human embryos in scientific 
research. The Chinese Society for Stem Cell Biology has already communicated with the 
International Society for Stem Cell Research and other societies about the human gene 
editing as well.34  
   
																																																								33	Ibid.		34	Ibid	
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  While the 2015 experiment on human zygotes that came out of China certainly 
shocked the world, it also planted a seed and laid the groundwork for future research of 
this nature.  
  On February 1st of 2016 the United Kingdom’s Human Fertilization and 
Embryology Authority (HFEA) became the world’s first national regulatory authority to 
endorse research on human embryos with CRISP-Cas9 technology.  The UK HFEA 
granted scientists in London permission to edit the genomes of human embryos (donated 
from IVF treatment) for research purposes.35 The scientists, Dr. Kathy Niakan and her 
team, report that they are interested in early human development and plan to alter genes 
that are active in the first few days after fertilization. 
   In her first experiment Dr. Niakan plans to block the activity of a ‘master 
regulator’ gene called OCT4, which is active in cells that go on to form the fetus. 36 Her 
team will allow the embryos to expire after seven days, even though they legally have up 
to 14 days to destroy them.37  
  More labs in the UK may pick up on this incredible opportunity to use CRISPR 
on human embryos to learn first hand about the development of the human body and 
launch their own studies. Other labs may want to work with human embryos to pursue 
disease eradication. The options are many.  
  The United States (under the FDA and the NIH) in contrast, does not allow this 
type of research to take place. It has imposed a temporary moratorium on both germline 																																																								35	Callaway, E. (2016). UK scientists gain license to edit genes in human embryos. Nature, 530(18). 
Retrieved February 4, 2016, from http://www.nature.com/news/uk-scientists-gain-licence-to-edit-genes-in-
human-embryos-1.19270  36	Ibid.		37	Wade, N. (2016, February 1). British Researcher Gets Permission to Edit Genes of Human Embryos. 
Retrieved February 4, 2016, from http://www.nytimes.com/2016/02/02/health/crispr-gene-editing-human-
embryos-kathy-niakan-britain.html?emc=eta1&_r=0  
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gene modification research and clinical application.38 Dr. Francis Collins, director of the 
US National Institutes of Health, said: “NIH will not fund any use of gene-editing 
technologies in human embryos. The concept of altering the human germline in embryos 
for clinical purposes … has been viewed almost universally as a line that should not be 
crossed.” The NIH also cites “serious and unquantifiable safety issues” associated with 
CRISPR-Cas9 as a reason for banning its’ use.  
 With very little international consensus on the matter of CRISPR research and 
clinical application, it is difficult to come to one’s own conclusions about how we should 
proceed in the regulation of this technology. I find it is necessary in this situation to work 
from the ground up: first by looking at the hard data on CRISPR from current studies to 
see what type of safety risks exist and then to consider the implications of these risks 
were we to move forward with the eventual clinical application of the technology.  
   
 
 
 
 
 
 
 
 
 
 
																																																								38	Araki, Motoko, and Tetsuya Ishii. "International Regulatory Landscape and Integration of Corrective 
Genome Editing into in Vitro Fertilization." Reproductive Biology and Endocrinology, November 24, 2014.  	
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III. Safety  
Safety Concerns associated with Clinical Application  
 The first major safety concern associated with CRIPSR-Cas9 germline gene 
editing are the off-target effects that can occur in the process of adding and deleting 
genes from the human genome. The CRISPR-Cas9 system utilizes nucleases that are 
supposed to cut the DNA at a very specific site. However, sometimes things go awry and 
the nucleases create cuts in other places in the DNA, leading to these off-target changes. 
Even if the double stranded break occurs in the correct location, there can be 
complications when the error-prone non-homologous end-joining pathway attempts to 
repair the breaks, which can result in off target effects as well.  
 If enough off-target effects occur, it could lead to the deactivation of essential 
genes. Without the proper functioning of all essential genes the embryo could grow up as 
an adult to experience other troublesome genetically related health issues. Mutations in 
other genes could also lead to oncogenesis (the process by which normal cells are 
transformed into cancer cells) if the mutations were numerous and severe enough. In 
some circumstances, off-target effects may also lead to chromosomal rearrangements,39 
which could cause major health issues down the road.  
 Mosaicism is another safety concern. Mosaicism refers to the phenomenon that 
occurs when a gene editing treatment only effectively edits some of the cells in a zygote, 
leaving the others untouched. In this scenario it is highly unlikely that the treatment 
would be effective.  
																																																								39	Ibid	
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 The results of the experiment conducted in China on triponuclear zygotes 
confirmed the legitimacy of these safety concerns. To begin, Liang, P et al. (2015) 
reported a targeting efficacy rate of only around 52%. Targeting efficiency, or percentage 
of desired mutation achieved, is one of the most important parameters in assessing a 
genome-editing tool.40 The targeting efficiency of CRISPR-Cas9 fares better than 
previous methods such as TALENs or ZFNs, yet there is lots of room for improvement. 
A rate of 52% targeting efficiency is not nearly high enough for this technology to be 
considered usable in a clinical setting. The risks are far too high that the embryo would 
grow up to have serious genetic problems caused by gene therapy.  
 In the experiment notable off-target mutations occurred as well. Two candidate 
off target sites found were within exons, which are essential coding regions of a gene.  
Furthermore, Liang P.et al’s (2015) search for off-target effects only covered a fraction of 
the genome and thus the authors assume their reported numbers of off-target mutations 
were very much underestimated.41 
 While we have been focusing on the potential safety problems that could arise 
with the use of CRISPR-Cas9, it is also it is also important to look at the best-case 
scenario of a new technology when thinking about how to proceed in regulating its future 
use.  In the best-case scenario CRIPSR is capable of less than 1 error per 300 trillion base 
pairs 42. This is significant if you consider that there are 3 billion base pairs in the human 
																																																								40	Reis, A. (2014). CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology. 
Retrieved from https://www.neb.com/tools-and-resources/feature-articles/crispr-cas9-and-targeted-genome-
editing-a-new-era-in-molecular-biology  41	Liang,	P.,	Xu,	Y.,	Zhang,	X.,	Ding,	C.,	Huang,	R.,	Zhang,	Z	Huang,	J.,	Lv,	J.,	Xie,	X.,	Chen,	Y.,	Li,Y.,	Sun,	Y.,	Bai,	Y.,	Songyang	Z.,	Ma,	W.,	Zhou,	C.,	Huang,	J	(2015).	CRISPR/Cas9-mediated	gene	editing	in	human	tripronuclear	zygotes.	Protein	&	Cell,	6(5),	363–372-363–372.	doi:10.1007/s13238-015-0153-5	42	Tsai,	S.	Q.	et	al.	Nature	Biotechnol.	33,	187–198	(2015). 
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genome, since it points to the fact that in the best case scenario we could be looking at a 
rate of close to no mutations. 
 On the first day of the International Summit on Gene Editing in Washington D.C., 
Keith Joung from Massachusetts General Hospital and Harvard Medical School spoke 
about the work his lab has done on improving safety issues related to the CRISPR-Cas9 
system. His team has been focusing on developing methods for defining the off-target 
effects of these nucleases and improving their specificity, which could greatly increase 
overall safety of the system. 
 As Joung himself admits, there still needs to be more research needs done to help 
determine which one or two techniques will give us the best ability to identify where off- 
target mutations will occur. The work remains promising however, and if kept up a 
breakthrough in safety and efficacy could be made. 
 Other labs currently are also using different techniques to identify off-target 
effects, including IDLV Capture, GUIDE-seq, HTGTS, Digenome-seq, and BLESS. All 
of these new methods have the potential to increase the safety of CRISPR-Cas9.  By 
looking at where off target effects are likely to occur and then tweaking the CRISPR 
system in accordance, scientists can potentially reduce the number of off-target effects 
and make sure they happen in places where they wont cause too much trouble, such as 
introns in the genome.  
 Additionally, Fu Y. et al (2014) found that there can be a 10,000-fold increase in 
target specificity when a certain type of RNA, truncated (17 or 18 base pair) sgRNA is 
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used.43 If truncated RNA could be used it might vastly decrease the number of off-target 
mutations that would occur with the use of CRISPR-Cas9 on human zygotes.  
 With continued research, another breakthrough could be the discovery of similar 
but potentially more powerful system than CRISPR-Cas9. Feng Zhang from the Broad 
Institute of Harvard and MIT talks about the fact that since CRISPR-Cas9, ZFNs and 
TALEN systems are all systems that come from nature there are likely to be even more 
systems waiting to be discovered. 44 Continuing with research could allow for a 
breakthrough of equal or greater scale than CRISPR-Cas9. At the high speed that 
scientists are carrying out research and the rate at which breakthroughs are occurring, a 
new piece of technology with a naturally higher specificity could indeed be discovered.  
  In summary, there are legitimate safety concerns connected to the clinical use of 
CRISPR-Cas9. After reviewing the current literature, it is clear that proceeding with the 
clinical application of CRISPR-Cas9 right now would be too dangerous for a future child. 
Devastating off-target effects occurring with the use of this technology are not something 
that can be tolerated when it comes real human embryos. Thus, at this stage in the 
development of CRISPR-Cas9 technology the potential benefits would not outweigh the 
serious risks involved with its use.  
 However, although unsafe to use currently, the research being done recently on 
improving safety of CRISPR holds much hope. If research continues, there is no reason 
to believe that there wouldn’t be a breakthrough in safety that could shift perspectives on 
clinical application of CRISPR-Cas9. We should invest and encourage ethical research of 																																																								43	Fu	Y.	et	al.	Improving	CRISPR-Cas	nuclease	specificity	using	truncated	guide	RNAs.	Nat.	Biotech.	(2014).	32:279-284		44	Zhang,	Feng.	(2015,	December	1)	Scientific	Background	on	Gene	Editing		
Technologies	[Video	file].	Retrieved	from	https://vimeo.com/album/3703972/video/149184118	
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for the sake of knowledge itself and perhaps with the goal of eventual clinical application 
as well.  
 This next chapter will focus on the most relevant ethical questions surrounding 
the use of CRISPR-Cas9 technology on human zygotes. While safety of a technology is 
certainly a very important part of the ethics discussion, there are other factors that should 
be considered as well including the potential for misuse (non-medical application) and 
accessibility of the technology. I will compare CRISPR to another reproductive 
technology, IVF, to provide further reference and context for my eventual conclusion 
about how to approach use of this technology in an ethical way.   
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IV. Ethics     
 Ethical debates surrounding new technologies can act as a bridge between science 
and society45 by joining together issues surrounding rights of patients, the safety of a 
technology, and the societal implications of its’ use. In this chapter I will present a 
number of ethical concerns brought up when considering the future clinical application of 
CRISPR-Cas9 on human zygotes.  By comparing CRISPR to other reproductive 
technologies and by quantifying certain claims, I will examine the main arguments put 
forth currently in banning the technology and challenge negative initial reactions 
surrounding its’ use. While CRISPR-Cas9 is not an appropriate form of preventative 
medicine right now, none of the ethical questions raised warrant a permanent ban on the 
technology either.  
 To begin, many of the ethical questions that exist with CRISPR-Cas9 are part of 
larger ongoing ethical discussions have been brought up before with other reproductive 
technologies, such as in vitro fertilization. In bioethicist John A. Robertson’s words, 
gene-altering technologies bring up the standard menu of “competing interests including 
the dignity of human reproduction, interests of women and children, and ideals about 
family.”46 
 IVF was met with skepticism and worry, just as CRISPR-Cas9 is today. 
Geneticist Lee Silver, who lived through the IVF debates, recounts that “the idea you 
could take a human embryo which you’ve created in the Petri dish, which is already very 																																																								45	Haker,	Hille	(2015,	December	1) Societal Implications of Emerging Technologies	[Video file]. Retrieved	from	https://vimeo.com/album/3703972/video/149190913	46	Assisting	Reproduction,	Choosing	Genes,	and	the	Scope	of	Reproductive	Freedom	John	Robertson,	https://law.utexas.edu/faculty/jrobertson/assisting-reproduction-choosing-genes.pdf	
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unnatural and abnormal, and then take that embryo and put it back into a woman’s uterus 
and have a baby born, was appalling to most people. Even to scientists and most other 
doctors it felt uncomfortable.”47 Robin Marantz Henig elaborates on this, explaining how 
people believed that by combining eggs and sperm in a Petri dish you ran the risk of 
chromosomal damage and “creating monsters”. Some critics of IVF were so put off by 
the idea of creating a baby in a test tube that they referred to these children as “Franken 
babies”.  
 James Watson, one of the scientists who helped discover DNA actually told the 
pioneer of IVF, Robert Edwards “you can only go on with you work if you accept the 
necessity of infanticide. There are going to be a lot of mistakes. What are we going to do 
with the mistakes?”48. Robert Edwards and research partner Patrick Steptoe were accused 
of trying to create a eugenic world with their new technology and faced moral 
condemnation for this.49  
 Amidst the heated debate surrounding IVF, the first IVF baby, Louise Brown, was 
born without complications in 1978 in the UK. Bioethicist Arthur Caplan recalls how this 
birth silenced many of the critics and shifted attitudes towards IVF, with many infertile 
couples now wanting to try it.  Today, IVF is a popular alternative to “traditional” 
reproduction and there are more than 5 million people worldwide who were born with the 
help of this technology without any harmful side effects.  
 Similar worries that surrounded the safety of IVF then, now surround CRISPR 
safety today. Just as people feared IVF could rearrange chromosomes, opponents of 																																																								47	The Pros and Cons of IVF. WGBH. Retrieved March 14, 2016, from 
http://www.pbs.org/wgbh/americanexperience/features/general-article/babies-pros-and-cons/	48	Ibid.  49	Kevles, Daniel. (2015, December 1) Scientific Background on Gene Editing Technologies [Video file]. 
Retrieved from https://vimeo.com/album/3703972/video/149182565	
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CRISPR-Cas9 fear that its’ off-target mutations could cause permanent chromosomal 
damage in future generations.   
 While IVF mimics what already occurs inside a woman’s body when a sperm 
fertilizes an egg, cutting target DNA with CRISPR-Cas9 is unlike anything that happens 
naturally in an embryo during development. In this way, CRISPR-Cas9 germline editing 
is completely unchartered territory. Fear surrounding CRISPR technology is certainly 
connected to its novelty and potential dangers.  
 The Liang Et al. (2015) paper coming out of China did much to further heighten 
concerns about the safety of CRISPR technology with its reporting of off-target 
mutations and mosaicism, and fueled arguments for banning the technology completely. 
While these results are important and rightfully inform how we view CRISPR technology 
currently, we must remember that this was only one study, and the very first of its kind.  
Following in line with most other scientific research, first attempts are likely to be the 
least successful. 
  Scientific research is like a complex puzzle. At times pieces will fit together and 
an image will come through, but many other times you are playing around with different 
parts, theorizing how they could relate to one another. Most scientific breakthroughs of a 
large scale are the result of hundreds of failures, each one bringing us closer to an 
important discovery. Thus by only looking at this single experiment and concluding that 
CRISPR is unsafe to use, we would be doing nothing more than letting fear dictate where 
we choose to focus our attention.   
 Another reason that opponents of CRISPR cite for banning the clinical application 
of the technology has to do with its potential for non-medical and eugenic use. CRISPR-
	 31	
Cas9 technology is unique because it can be used to identify the function of genes never 
before explored. On the one hand this is incredibly important knowledge to have about 
the human genome. On the other hand there is the potential to misuse this knowledge for 
non-medical reasons. Some worry that identifying certain “good” and “bad” genes could 
lead to a push by interested parties to enhance the expression of these genes or get rid of 
them entirely.  
  Interestingly, concerns surrounding the eugenic potential of CRISPR-Cas9 
technology today also mirror concerns surrounding the eugenic potential of IVF 
technology when it first came out.  As Daniel J. Keyles, one of the speakers from the 
International Summit on Human Gene Editing in D.C. put it, “every past advance in the 
knowledge and technologies of genetics and human reproduction has been shadowed by 
the long reach of eugenics, and so it is with CRISPR-Cas9”.50  
 Bioethicist Arthur Caplan remembers the fear circulating that people would use 
IVF to have children with certain desirable traits like intelligence or athleticism. Some 
truly believed that soon everyone would be having children in test tubes and that 
marriage would be replaced by laboratory breeding like in Huxley’s Brave New World.51 
Yet as we can see, IVF has yet to create a new breed of super children as people feared it 
would.   
 While it is not out of the realm of possibility that CRISPR- Cas9 could be used for 
non-medical reasons, there are also practical barriers that stand in the way of this easily 
occurring. Opponents of CRISPR worry that it will be used to create “designer babies”. If 																																																								50	Kevles, Daniel. (2015, December 1) Scientific Background on Gene Editing Technologies [Video file]. 
Retrieved from https://vimeo.com/album/3703972/video/149182565 51	The Pros and Cons of IVF. WGBH. Retrieved March 14, 2016, from 
http://www.pbs.org/wgbh/americanexperience/features/general-article/babies-pros-and-cons/	
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it were a simple task to mold a child exactly in one’s image then there would be 
legitimate cause for concern. However, this is not the case.    
 In reality, a very complicated and delicate interplay between epigenetic factors, 
environmental influences, and actual genetic code is at play in determining the traits a 
child will be born with and grow into (height, skin color, intelligence, personality, mental 
illness). For instance, height is a multifactorial trait with as many as 400 genes in play. 
Tweaking all 400 genes of these genes is simply not a feasible task to perform on 
embryos. Epigenetics also plays a large role in determining the expression of certain 
genes, thus editing genes alone does not always guarantee a specific phenotypic outcome. 
 Furthermore, with less tangible traits such as intelligence and mental health there 
are still so many things that we do not understand. While most scientist can agree that it 
is the combination of nature (genes) and nurture (environment) that leads to the 
development of these types of traits, no one knows exactly how much each contributes. 
 Take intelligence for instance. Something so subjective and difficult to measure is 
going to be even harder to pin point in our DNA. While we may be able to eventually 
target genes that are involved in memory strength or quantitative reasoning abilities, it is 
highly unlikely that changing a couple of genes could boost a child’s IQ significantly. 
There are too many other factors that can determine how successful a child is or how 
“intelligent” they are considered, including the education of their parents, what school 
they attend, whether they are encouraged to think creatively, their self esteem, etc. 
  In conclusion, it is a vast oversimplification to say that CRISPR editing would be 
so powerful that it could completely change children and make them into something they 
wouldn’t otherwise be. Furthermore, even if the field of genetics were to progress so 
	 33	
much that we could pinpoint exact genes that cause certain traits, it wouldn’t mean that 
parents would immediately start demanding that their children be engineered to have 
these traits. Allowing the medical use of CRISPR-Cas9 treatment to take place would not 
inevitably lead to the eugenic use of the technology, as some fear. The slippery slope 
argument, while compelling, tends to overlook very legitimate barriers.  
 The next ethical issue I will bring up involves the rights of the embryo undergoing 
the CRISPR-Cas9 germline gene therapy. I will review arguments from those who 
believe that using CRISPR technology violates the rights of the future child as well as 
arguments from the opposing side who believe that there may in fact be a moral 
obligation to use this technology to prevent children from developing genetic diseases.  
 In the case of CRISPR-Cas9 germline modification, parents or legal guardians 
would have to give their proxy consent in order for their embryo to undergo gene therapy. 
The legal age of consent for participating in a clinical trial is 18 years old, so if a child is 
under that age then a parent or legal guardian can act as a proxy to make the decision on 
the child’s behalf.  Some feel strongly that giving consent on behalf of an embryo is 
wrong, especially if that decision could expose the embryo to harm.  
 Dr. Hille Haker argues that using CRIPSR-Cas9 technology on embryos “violates 
the freedom rights of future children” and “disregards the future child in the 
considerations, especially with respect to a life of monitoring”52. Her rationale behind this 
is that the parent or guardian giving consent is making a life altering decision for the 
child based only on what they imagine he or she would want. Dr. Joanna Smolenski 
agrees with Haker. Smolenski argues that parents cannot accurately represent the interests 
																																																								52	Ibid.		
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of their child if they are not born yet, and thus their “proxy consent would be based 
entirely on unjustifiable parental speculation”.53 Smolenski would likely feel more 
comfortable with the use of the therapy if consent could be obtained from the actual child 
undergoing the treatment, or from their parents after they talked directly to their child. 
Unfortunately, this clearly cannot take place with germline gene therapy on an embryo. 
Thus we are faced with an ethical dilemma: can parents rightfully make the decision to 
edit their child’s DNA or not?  
 John Harris, a bioethicist from the University of Manchester in the UK believes 
that they can. He argues that since these future children cannot give consent themselves, 
it is our moral imperative to make the best decision we can for them in the way we think 
they would decide if they could. As he puts it, “absence of consent cannot be the reason 
we do not make decisions for future persons, it is the reason that we have to make 
decisions on their behalf.” He feels that if there is a legitimate medical intervention that 
would prevent a child from living a life of suffering from disease, then it ethically can be 
used on the child with consent from the parents.  
 I agree strongly with Harris in his stance on consent. A parent’s proxy consent, 
which is not based on “unjustifiable speculation” as Smolenski posits, should be upheld 
as the next best alternative to actual consent. While it is technically speculative, it is not 
at all unjustified. It is in fact based on a strong parental desire to give their child the best 
chance at a healthy and normal life. Parents generally make the most careful decisions 
regarding their children’s health, so if they decided to allow doctors to edit their child’s 
DNA, it would likely only be after much deliberation and after weighing of all other 																																																								53	Joanna	Smolenski	(2015)	CRISPR/Cas9	and	Germline	Modification:	New	Difficulties	in	Obtaining	Informed	Consent,	The	American	Journal	of	Bioethics,	15:12,	35-37,	DOI:	10.1080/15265161.2015.1103816	
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options.  Parents that live with a genetic disease themselves may decide that their quality 
of life is low enough that any chance to free their child from the grasp of the disease 
would be worth taking. 
 Furthermore, parents make decisions on the behalf of their children all the time. 
From the diet they feed them, to the school that they enroll them in, to the genes they pass 
down to them, they both intentionally and unintentionally altered the course of their 
children’s lives. While a parent’s decision to make changes to their child’s genome is of 
course different then feeding them fast food for dinner, it is still an intervention that a 
parent makes in their child’s life that may shape their future.  
 Saculescu et al (2015), like Harris, view CRISPR technology in terms of its 
potential. They feel that there is a moral imperative to continue with CRISPR-Cas9 
research54 because of the lives that could be changed for the better if it would become 
safe enough to use clinically. They talk about the huge number of children, nearly eight 
million, born each year with serious birth defects that are partially or totally genetic in 
origin as the reason. They believe that fear of the future is an insufficient reason to halt 
research on the technology. In their eyes, anxiety surrounding new technology has 
historically always existed (offering the Internet and mobile phones as examples) 55 and 
thus the fear surrounding CRISPR is nothing new.  
 I agree that fear of the unknown cannot be a reason to avoid pursuing something 
that could be incredibly helpful for future children. The absence of consent from a future 
child cannot be the reason we do not go ahead with research and eventual clinical 																																																								54	Savulescu, Julian, Jonathan Pugh, Thomas Douglas, and Christopher Gyngell. "The Moral Imperative to 
Continue Gene Editing Research on Human Embryos." Protein & Cell 6.7 (2015): 476–479. Web. 	55	Savulescu, Julian, Jonathan Pugh, Thomas Douglas, and Christopher Gyngell. "The Moral Imperative to 
Continue Gene Editing Research on Human Embryos." Protein & Cell 6.7 (2015): 476–479. Web.	
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application of CRISPR-Cas9 when there is much potential that this technology holds. 
Although there is a risk of harm inherent in gene editing, the potential gain of a life free 
from the burden of a genetic disease makes the risk justifiable. Additionally, as research 
continues, the CRISPR system will likely become much safer to use and thus chances of 
disastrous effects from the treatment will become drastically lower.  
 Another fact to consider when reviewing ethical arguments for and against the use 
CRISPR technology are whether or not we have given equal weight to opinions from all 
stakeholders. Thus far, the voices of scientists and ethicists have been the loudest in the 
conversation. While scientists may feel they are making a wise decision on behalf of 
patients, they may actually be inserting their own more conservative beliefs into the 
conversation and silencing the voices of those who will actually be directly affected by 
this technology. As reporter Antonio Regalado pointed out, even during the summit in 
Washington, which sought to incorporate all voices, no practicing IVF doctors were 
involved directly, and only one patient advocate was invited to present.56 
 Patients and family members of those living with genetic diseases should have a 
platform by which their voices can be heard as well, as they are the ones with the most 
“skin in the game”. Regalado has attempted to counter the ones sidedness of the 
conversation by interviewing people with genetic disorders to see how their responses 
would compare to the discourse already circulating at the professional level. One man 
with Huntington’s Disease he talked to, Jeff Carroll, a 38-year-old neuroscientist, said he 
																																																								56	Regalado, A. (2015, December 2). Patients Favor Changing the Genes of the Next Generation with 
CRISPR. Retrieved March 16, 2016, from https://www.technologyreview.com/s/544141/patients-favor-
changing-the-genes-of-the-next-generation-with-crispr/ 		
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would be very much in favor of gene editing. He quotes him saying, “please please do 
mess with our DNA”.  
 Regalado also cites a review by the MIT Technology Review that asked several 
families who have dealt with devastating genetic illness about what they thought of 
CRISPR. They all responded saying they would be in favor of CRIPSR-Cas9 germline 
gene editing. Regalado forecasts that the nature of the debate will change significantly 
once patients get involved. He talks about one woman, Sharon Terry, CEO of a patient 
group called Genetic Alliance, who says she has received many emails from families who 
expressed their support for the technology. If more patients and advocacy group organize 
and push for the use of this technology, it will difficult to come up with a strong 
reasoning beyond safety concerns as to why they should not have access to the 
technology. 
 Another area where the opinions of patients and scientists clash is whether 
CRISPR even has a place in medicine when technologies such as pre-implantation 
diagnosis (PGD) exist and can be used safely on embryos instead. PGD checks the genes 
of an embryo created through in-vitro fertilization prior to implantation57, and has been 
used successfully to screen for over 250 genetic conditions including cystic fibrosis, 
spinal muscular atrophy, and late-onset Huntington Disease.58 Scientist Eric Lander, 
director of the Broad Institute, believes that PGD is the most logical technology to use 
instead of CRISPR-Cas9.  
 																																																								57	Pre-implantation genetic diagnosis (PGD). (2014, April 1). Retrieved from 
http://www.hfea.gov.uk/preimplantation-genetic-diagnosis.html  58	Ishii,	T.	et	al.	(2013)	Ethical	and	legal	issues	arising	in	research	on	inducing	human	germ	cells	from	pluripotent	stem	cells.	Cell	Stem	Cell	13,	145-148	
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 Lander argues,  
If we really care about avoiding genetic disease, germline editing is not 
the first, second, third, or even fourth thing to worry about. Most people 
are not even aware they are carriers. Letting them know and allowing 
them to use PGD would be the best. 
 
 Yet a conversation with patient Jeff Carroll gives us reason to think that perhaps 
Lander is not seeing the full picture. Carroll explains how his family was among the first 
Huntington’s families to try PGD when the technology became commercially available in 
the early 2000s. The procedure was successful, with doctors locating two unaffected 
embryos out of five. His wife had twins, a boy and a girl.  However, many families 
haven’t been as lucky, he goes on to explain. They don’t get any healthy embryos, or the 
IVF procedure is unsuccessful. He argues, “PGD is a hack, it’s not a fix. And you lose 50 
percent of your embryos, which is not trivial.” He concludes, “It’s intellectually tempting 
to say PGD can fill the niche. I think gene editing would be a major boon to families.”  
 PGD, while effective in many cases, does not ensure the birth of a healthy child in 
all situations. When one or both partners have the disease allele of a homozygous 
dominant genetic disease, using CRISPR to correct the mutation would be the only way 
for them to have a genetically related healthy child. In the case of a genetic disease such 
as Huntington’s, the likelihood that the child will develop the disease is as follows:   
• Mother and father both have two copies of the disease allele: 100% chance of 
embryo developing Huntington’s  
• Mother has two copies of the disease allele, father has one copy: 100% chance 
	 39	
• Mother has two copies of the disease allele, father has no copies of disease allele: 
100% chance 
• Mother and father both have one copy of disease allele: 75% chance 
• Mother has one copy of disease allele, father has no copies of disease allele: 50% 
chance 
  When the embryos have a 100% chance of developing Huntington’s PGD 
wouldn’t do much, because there would be no disease free embryos to select for 
implantation. In any of the above situations, CRISPR-Cas9 germline gene therapy could 
be used on an unhealthy embryo to correct for the mutation causing Huntington’s so the 
couple could have a chance at giving birth to a healthy and genetically related child. No 
embryos would be need to be discarded, and as long as the woman could produce one 
embryo there would be a chance that she could have a successful pregnancy.   
 Another reason to pursue CRISPR as well is the fact that CRISPR-Cas9 germline 
editing may be a wiser option from a public health standpoint. With pre-genetic diagnosis 
doctors can choose an embryo that will grow up to be healthy, unaffected by a genetic 
disorder. However, this child may still be a carrier for the disorder and thus the disease 
will certainly show up again farther down the generational line. If CRISPR-Cas9 therapy 
is successful and off target mutations are kept at bay, germline gene editing offers a way 
to reduce the prevalence of certain heritable diseases for a long time in certain families.  
 Robert Sade, head of the bioethics department at the Medical University of South 
Carolina also talks about the benefits of germline therapy over somatic cell therapy. He 
says that while diseases such as cystic fibrosis could be treated in the future with somatic 
gene therapy (making changes in the DNA of matured and differentiated body cells as 
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opposed to germline cells) it would be far more efficient to use a single germline 
treatment than to treat the disease each time it appears in subsequent generations. 
Additionally, he notes, from a public health perspective germline therapy would more 
effectively conserve future health care resources.  
 George Church agrees with Sade that germline therapy is superior to somatic cell 
therapy. He talks about how germline editing may in fact be safer in some circumstances 
because editing a single germ cell is safer than treating millions of somatic cells since 
each treatment of a cell adds to the collective risk of the cell becoming cancerous. 59  
Each time a cell is edited using CRIPSR there is a chance that an oncogene (a gene that 
can transform a healthy cell into a cancerous cell) could be turned on or a tumor 
suppressor gene could be turned off. The more times this process is used, the greater the 
chance that this could occur.  
 However, if germline therapy using CRISPR were to be carried out it would need 
to be accessible in terms of cost. At least initially the cost of CRISPR treatment could be 
a barrier to its’ use. Yet like most technologies, its price could decrease greatly over time. 
For example, the cost of genome sequences has exponentially decreased since the 
technology came out.  The starting price was $100 million to sequence a single genome 
in 2001 and this price plummeted to $1,000 in 2015.  
 
																																																								59	Church,	George	(2015,	December	1)	Applications	of	Gene	Editing	Technology:	Human	Germline	
Modification	[Video	file].	Retrieved	from	https://vimeo.com/album/3703972/video/149188798	
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Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP) Available 
at: www.genome.gov/sequencingcosts. Accessed February 13,2016.  
 
 
 A similar trend could happen with CRISPR if it was put on the market and its use 
became more widespread. High prices as barriers to access often occurs with the release 
of most new medical technology, and while this is unfortunate, I do not see it as a reason 
to not pursue germline gene editing using CRISPR-Cas9.   
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V. Conclusion  
 The development of CRISPR technology has already pushed us to expand our 
notion of what we considered possible in science and medicine. As we stand at this new 
frontier, we are faced with the question of how to move forward. Considering eventual 
clinical use of CRSIPR-Cas9 on human zygotes forces us to question our moral position 
on the rights of embryos and to what extent we should restrict use of technology that 
could harm them, but also greatly help them. The CRISRP quandary combines important 
questions surrounding the safety of a new and powerful technology with the implications 
of its use on the human germline.   
 For safety and other reasons, CRISPR-Cas9 is not yet ready to be used clinically 
use on human zygotes. A temporary moratorium on clinical application, as the 
International Summit on Human Gene Editing put forth, is advisable. A moratorium of 
this nature would allow safety concerns to be sorted out and ethical issues to be further 
clarified, and would allow for suitable regulatory policy to be developed as well.  
 Opponents such as Hille Haker want to ban use of CRISPR-Cas9 on human 
zygotes and put a moratorium on research using human zygotes for up to two years60. 
This is not the way to proceed. A ban on the research and eventual application of this 
technology would deny those who are sick with genetic disease access to a potential 
technology that would prevent them from transmitting a terrible genetic disease on to 
their children. With time and careful research, making changes to the germline of human 
beings could be the next best medical intervention.  
																																																								60	Haker,	Hille	(2015,	December	1) Societal Implications of Emerging Technologies	[Video file]. Retrieved	from	https://vimeo.com/album/3703972/video/149190913	
	 43	
 George Church, a seasoned professor of genetics at Harvard Medical School 
argues against a ban saying, “banning human germline editing could put a damper on the 
best medical research and instead drive the practice underground to black markets and 
uncontrolled medical tourism, which are fraught with much greater risk and 
misapplication.” Barbara Evans adds, “You don’t want to ban the basic research that 
would resolve the uncertainty that’s causing you to have the moratorium”. Instead, she 
says, we should strive to create “policies that will force creation of evidence.” 
 Furthermore, banning CRISPR-Cas9 may not even be feasible. As Jennifer 
Doudna, one of the developers of CRISPR, explains, “a complete ban is impractical given 
the widespread accessibility and ease of use of CRISPR-Cas9”61 
  Doudna also outlines steps for what she believes will be the most prudent path 
forward in using the technology. First, she pushes for a standard method for measuring 
genome editing efficiency and off-target effects so research results can more easily be 
compared between researchers and clinicians. Next, she emphasizes the need for open 
communication to continue between experts in the genome-editing and bioethics 
communities as well as the public.62 This is a strong point in her plan. Involving the 
public in these conversations is crucial to ensure a diverse range of opinions will be put 
out and discourse will be kept open and inclusive.   
 Third, she talks about the need for an international consensus on ethically 
acceptable research and the need for regulation to evaluate the efficacy and specificity of 
genome-editing technologies.63  
																																																								61	Doudna, J. (2015). Embryo Editing Needs Scrutiny. Nature, 528. Retrieved April 27, 2016.  62	Doudna, J. (2015). Embryo Editing Needs Scrutiny. Nature, 528. Retrieved April 27, 2016.  63	Ibid	
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 I believe the best way to regulate safe research would be through the creation of 
an international regulatory body that could oversee all laboratory research activity. 
Scientists would submit their research proposals to the international regulatory body for 
approval before beginning their work, which would create a system of accountability and 
make rogue experiments a less likely occurrence going forward. Since degrees of 
regulation differ so greatly from country to country, it would be of the upmost benefit for 
there to be an international consensus on how research using human embryos should be 
carried out safely and ethically.  
 Safe research during this time is the best way to proceed forward until CRIPSR 
technology becomes safe enough to be considered an option for clinical use. In the words 
of Jonathan Kimmel,  
 
 We want to steward research in a way that is going to be sustainable. 
Catastrophic events in one isolated trial can destabilize, dramatically 
undermine efforts in other independent research and I think we want to 
have a collective effort going forward that is methodical and careful and 
likely to enable sustained scientific efforts.  
 
 If CRISPR-Cas9 technology were to develop a bad reputation due to results from 
one experiment, it could prevent development and use of CRISPR technology not only in 
the field of medicine, but in other important fields as well. Thus, over the next couple of 
years it will be crucial for countries to enforce research guidelines to ensure safety and 
ethical standards are adequately met.  
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 Another important task that an international regulatory body could spearhead 
would be the development of an agreed upon a minimum safety standard that CRISPR 
would have to reach before it could be even considered for use clinically on human 
zygotes.   
 This could take the form of a comprehensive calculation of efficacy based on 
objective measurements including the number of off-target effects, location of off-target 
mutations, and percentage of cells that were successfully edited. The minimum safety 
standard would be implemented to ensure that clinical CIRSPR treatments would not 
harm future embryos. An international consensus would provide scientists with an 
objective goal to reach towards in their research using CRISPR and would encourage 
better design of guide RNAs and other mechanisms affecting the efficiency of the 
CRISPR-Cas9 system.  
 The clinical application of CRISPR-Cas9 on human zygotes may not remain a far 
off notion much longer. We must rise to the occasion and seize upon the opportunity 
presented by this incredible new technology. Because there are legitimate reasons for 
choosing CRISPR-Cas9 over other technologies, I think it is wise to accept the 
inevitability of its use.   
 With this in mind, it makes the most sense to take steps towards regulating this 
technology is the best way that we can. Although it may be hard to imagine that CRISPR-
Cas9 could really be used to prevent genetic disease in human zygotes, a look back at the 
seeming impossibility of other reproductive technologies helps us to realize that the 
“seemingly impossible” can be realized. While it is only natural for a powerful 
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technology such as CRISPR-Cas9 to be feared, we must question the basis of these fears 
and not let them cloud our judgment moving forward.   
 CRISPR-Cas9 opens many options in the field of preventative medicine, ones that 
I believe society will soon be more than ready to handle with the proper international 
regulations in place, open communication, and the carrying out of transparent and safe 
research.   
 Thus, I conclude on a positive note. The development of CRISPR-Cas9 as a 
genome-editing tool is undoubtedly an incredible scientific advancement. This 
technology holds unique potential to become a powerful piece of preventative medicine 
and should thus be approached with hope and as well as a healthy dose of caution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
	 47	
 
Works Cited 
 
 
Araki, Motoko, and Tetsuya Ishii. "International Regulatory Landscape and Integration of Corrective 
Genome Editing into in Vitro Fertilization." Reproductive Biology and Endocrinology, November 24, 2014.  
 
Baltimore, D. et al. (2015) A prudent path forward for genomic engineering and germ line gene 
modification. Science 348, 36-38 
 
Braude, Peter. (2015, December 1) Applications of Gene Editing Technology: Human Germline 
Modification [Video file]. Retrieved from https://vimeo.com/album/3703972/video/149188729 
 
Callaway, E. (2016). UK scientists gain license to edit genes in human embryos. Nature, 530(18). 
Retrieved February 4, 2016, from http://www.nature.com/news/uk-scientists-gain-licence-to-edit-genes-in-
human-embryos-1.19270 
 
Church, George. “Perspective: Encourage the Innovators.” Nature. 528 
 
Church, George (2015, December 1) Applications of Gene Editing Technology: Human Germline 
Modification [Video file]. Retrieved from https://vimeo.com/album/3703972/video/149188798 
 
Cressey, D., Abbott, A., & Ledford, H. (2015). UK scientists apply for license to edit genes in human 
embryos. Nature. Retrieved from http://www.nature.com/news/uk-scientists-apply-for-licence-to-edit- 
 
Doudna, Jennifer, and Emmanuelle Charpentier. "The New Frontier of Genome Engineering with CRISPR-
Cas9." Science 346.6213 (2014). Web. <www.sciencemag.org>. 
 
Doudna, J. (2015). Embryo Editing Needs Scrutiny. Nature, 528. Retrieved April 27, 2016.  
 
Fu Y. et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotech. (2014). 
32:279-284 
 
G. Schwank et al., Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic 
fibrosis patients. Cell Stem Cell 13, 653–658 (2013). doi: 10.1016/j.stem.2013.11.002; pmid: 24315439 
 
Haker, Hille (2015, December 1) Societal Implications of Emerging Technologies [Video file]. Retrieved 
from https://vimeo.com/album/3703972/video/149190913 
 
Harris, John (2015, December 1) Societal Implications of Emerging Technologies [Video file]. Retrieved 
from https://vimeo.com/album/3703972/video/149190907 
 
Ishii, T. (2015). Germline genome-editing research and its socioethical implications. CellPress, 21(8) 
 
Ishii, T. et al. (2013) Ethical and legal issues arising in research on inducing human germ cells from 
pluripotent stem cells. Cell Stem Cell 13, 145-148 
 
J. E. Garneau et al., The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. 
Nature 468,67–71 (2010). doi: 10.1038/nature09523; pmid: 21048762 
 
Joanna Smolenski (2015) CRISPR/Cas9 and Germline Modification: New Difficulties in Obtaining 
Informed Consent, The American Journal of Bioethics, 15:12, 35-37, DOI: 
10.1080/15265161.2015.1103816 
	 48	
 
Joung, Keith. (2015, December 1) Scientific Background on Gene Editing  
Technologies [Video file]. Retrieved from https://vimeo.com/album/3703972/video/149184091 
 
Kahn, J. (2015, November 9). The Crispr Quandry. The New York Times. Retrieved from 
http://nyti.ms/1Ozx7pG  
 
Kevles, Daniel. (2015, December 1) Scientific Background on Gene Editing Technologies [Video file]. 
Retrieved from https://vimeo.com/album/3703972/video/149182565 
 
Knoepfler, P. (2015, April 24). The big blind spot on CRISPR for human embryo editing: PGD. Retrieved 
March 16, 2016, from http://www.ipscell.com/2015/04/crispr-versus-pgd/  
 
Ledford,H. (2015).Where in the world could the first CRISPR baby be born?. Nature, 530 Retrieved 
February 4, 2016, from http://www.nature.com/news/where-in-the-world-could-the-first-crispr-baby-be-
born-1.18542 
 
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z Huang, J., Lv, J., Xie, X., Chen, Y., Li,Y., 
Sun, Y., Bai, Y., Songyang Z., Ma, W., Zhou, C., Huang, J (2015). CRISPR/Cas9-mediated gene editing in 
human tripronuclear zygotes. Protein & Cell, 6(5), 363–372-363–372. doi:10.1007/s13238-015-0153-5 
 
Lovell, Robin (2015, December 1) Applications of Gene Editing Technology: Human Germline 
Modification [Video file]. Retrieved from https://vimeo.com/album/3703972/video/149188712 
 
M. Araki & Ishii Reprod. Biol. Endocrinol. 12, 108 (2014) 
 
M, Jimek. et al. Science 337, 816-821 (2012) 
 
M. Jinek et al., RNA-programmed genome editing in human cells. eLife 2, e00471 (2013). doi: 
10.7554/eLife.00471;pmid: 23386978 
 
M. Jinek et al., A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. 
Science 337,816–821 (2012). doi: 10.1126/science.1225829; pmid: 22745249 
 
 
On Human Gene Editing: International Summit Statement. (2015, December 3). Retrieved from 
http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=12032015a  
 
Pre-implantation genetic diagnosis (PGD). (2014, April 1). Retrieved from 
http://www.hfea.gov.uk/preimplantation-genetic-diagnosis.html  
 
R. Barrangou et al., CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 
1709–1712 (2007). doi: 10.1126/science.1138140; pmid: 17379808 
 
R. Barrangou, P. Horvath, CRISPR: New horizons in phage resistance and strain identification. Annu. Rev. 
Food Sci.Technol. 3, 143–162 (2012). doi: 10.1146/annurev-food-022811-101134; pmid: 22224556 
 
Regalado, A. (2015, December 2). Patients Favor Changing the Genes of the Next Generation with 
CRISPR. Retrieved March 16, 2016, from https://www.technologyreview.com/s/544141/patients-favor-
changing-the-genes-of-the-next-generation-with-crispr/  
 
Reis, A. (2014). CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology. Retrieved 
from https://www.neb.com/tools-and-resources/feature-articles/crispr-cas9-and-targeted-genome-editing-a-
new-era-in-molecular-biology  
	 49	
 
Robertson, John. Assisting Reproduction, Choosing Genes, and the Scope of Reproductive Freedom 
https://law.utexas.edu/faculty/jrobertson/assisting-reproduction-choosing-genes.pdf 
 
Sade RM, Khushf G. Gene therapy: ethical and social issues. J So Carolina Med Assoc 1998;94(9):406-410 
 
Savulescu, Julian, Jonathan Pugh, Thomas Douglas, and Christopher Gyngell. "The Moral Imperative to 
Continue Gene Editing Research on Human Embryos." Protein & Cell 6.7 (2015): 476–479. Web. 
 
The Pros and Cons of IVF. WGBH. Retrieved March 14, 2016, from 
http://www.pbs.org/wgbh/americanexperience/features/general-article/babies-pros-and-cons/ 
 
Tsai, S. Q. et al. Nature Biotechnol. 33, 187–198 (2015). 
 
Wade, N. (2016, February 1). British Researcher Gets Permission to Edit Genes of Human Embryos. 
Retrieved February 4, 2016, from http://www.nytimes.com/2016/02/02/health/crispr-gene-editing-human-
embryos-kathy-niakan-britain.html?emc=eta1&_r=0  
 
Y. Ishino, et al. (1987) J. Bacteriol. 169, 5429-5433 
 
Y. Ishino, H. Shinagawa, K. Makino, M. Amemura, A. Nakata, Nucleotide sequence of the iap gene, 
responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene 
product. J. Bacteriol. 169, 5429–5433 (1987). pmid: 3316184 
 
Y. Wu et al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13, 659–
662 (2013). doi: 10.1016/j.stem.2013.10.016; pmid: 24315440 
 
Zhang, Feng. (2015, December 1) Scientific Background on Gene Editing  
Technologies [Video file]. Retrieved from https://vimeo.com/album/3703972/video/149184118 
 
Zhang, F. (Director). (2014). Genome Editing with CRISPR-Cas9 [Motion picture]. USA. 
https://www.youtube.com/watch?v=2pp17E4E-O8 
 
